Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Rhea-AI Summary
Whitehawk Therapeutics (Nasdaq: WHWK) announced that President and CEO Dave Lennon, PhD, will join a virtual fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026, at 3 PM ET. A live and replay webcast will be available on the investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – WHWK
On the day this news was published, WHWK declined 7.84%, reflecting a notable negative market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $20M from the company's valuation, bringing the market cap to $232.43M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Private placement | Positive | +25.8% | Announced approximately $87.5M private placement to extend ADC pipeline funding runway. |
| May 07 | Quarterly earnings | Negative | -5.1% | Reported Q1 2026 results with higher R&D spend and net loss amid ADC transition. |
| Apr 19 | Preclinical data | Positive | +2.9% | Presented AACR 2026 data showing tumor regressions and favorable ADC tolerability. |
| Apr 16 | Investor fireside chat | Negative | -2.8% | Announced CEO participation in a virtual fireside chat with webcast replay access. |
| Apr 10 | Target validation data | Negative | -4.5% | Presented SGO data confirming strong MUC16 expression supporting HWK‑016 development. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news produced both positive and negative 24-hour moves, with reactions generally matching the direction of each announcement’s price impact rather than showing a consistent pattern.
Over the last month, WHWK reported Q1 2026 results, advanced its ADC pipeline and executed an $87.5M private placement that lifted cash runway into the second half of 2028. Scientific updates at AACR and SGO 2026 highlighted HWK‑007, HWK‑016 and HWK‑206, plus MUC16 targeting. Investor events, including prior fireside chats, drew modest mixed reactions. Today’s Stifel oncology forum participation fits into this ongoing pattern of regular visibility and clinical-stage updates.
Key Terms
antibody drug conjugate (adc) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact:
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum-302773247.html
SOURCE Whitehawk Therapeutics, Inc.